Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Atrium Therapeutics, Inc. RNA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$54.50
+288.7%

Atrium Therapeutics, Inc. (RNA) is a Biotechnology company in the Healthcare sector, currently trading at $14.02. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is RNA = $55 (+288.7% upside).

Valuation: RNA trades at a trailing Price-to-Earnings (P/E) of -3.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.15.

Financials: revenue is $19M, +29.5%/yr average growth. Net income is $77M (loss), growing at -0.4%/yr. Net profit margin is -411.9% (negative). Gross margin is 100% (+15 pp trend).

Balance sheet: total debt is $4M against $207M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 6.53 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $278M.

Analyst outlook: 7 / 16 analysts rate RNA as buy (44%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).

$54.50
▲ 288.73% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Atrium Therapeutics, Inc., the average price target is $54.50, with a high forecast of $59.00, and a low forecast of $50.00.
Highest Price Target
$59.00
Average Price Target
$54.50
Lowest Price Target
$50.00

RNA SharesGrow Score Overview

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RNA

✓
VALUE Pass
100/100
RNA trades at a trailing Price-to-Earnings (P/E) of -3.1 (S&P 500 average ~25). Forward PEG 0.15 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $55, implying +292.3% from the current price $14. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
RNA: +29.5%/yr revenue is, -0.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet RNA: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 6.53 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
RNA: Gross margin is 100% (+15 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 7 / 16 analysts rate RNA as buy (44%). Analyst consensus target is $55 (+292.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
RNA: Net profit margin is -411.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range11.95-16.77
Volume365.88K
Avg Volume (30D)1.07M
Market Cap$217.52M
Beta (1Y)0.00
Share Statistics
EPS (TTM)-4.48
Shares Outstanding$17.11M
IPO Date2026-02-27
CEOKathleen Gallagher
Financial Highlights & Ratios
Revenue (TTM)$18.62M
Gross Profit$18.62M
EBITDA$-76.49M
Net Income$-76.68M
Operating Income$-76.81M
Total Cash$270M
Total Debt$3.67M
Net Debt$-266.33M
Total Assets$278.35M
Price / Earnings (P/E)-3.1
Price / Sales (P/S)11.68
Analyst Forecast
1Y Price Target$54.50
Target High$59.00
Target Low$50.00
Upside+288.7%
Rating ConsensusHold
Analysts Covering16
Buy 44% Hold 56% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS04965N1046

Price Chart

Track all markets on TradingView
RNA
Atrium Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
11.95 52WK RANGE 16.77

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 SWTX
SWTX
SpringWorks Therapeutics, Inc.
$46.99
+0.02%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message